ARCH Venture Fund IX, L.P. - Significant Ownership

Signature - Title
/s/ ARCH Venture Partners IX, L.P. - its General Partner
Location
Chicago, IL
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by ARCH Venture Fund IX, L.P..

Significant Ownership of ARCH Venture Fund IX, L.P.

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
SANA Sana Biotechnology, Inc. Common Stock, par value $0.0001 per share 17.3% $164M 46.1M Robert Nelsen Sep 30, 2025
LYEL Lyell Immunopharma, Inc. Common Stock par value $0.0001 per share 13.1% $16.1M 36.6M Robert Nelsen Dec 31, 2024
LYEL Lyell Immunopharma, Inc. Common Stock par value $0.0001 per share 13% $44.8M 2.76M ARCH Venture Fund IX, L.P. Sep 30, 2025
BEAM Beam Therapeutics Inc. Common Stock par value $0.01 per share 4.6% $71.2M 4.6M 0% Robert Nelsen Mar 31, 2025
OMIC Singular Genomics Systems, Inc. Common Stock par value $0.0001 per share 0% $0 0 ARCH Venture Fund IX, L.P. Feb 21, 2025

Schedules 13D/G Reported by ARCH Venture Fund IX, L.P.:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Date Filed
* An asterisk sign (*) next to the price indicates that the price is likely invalid.